- Organon (OGN, Financial) appoints Ramona A. Sequeira to its Board of Directors, starting July 1, 2025.
- Sequeira brings over 30 years of pharmaceutical industry experience to the board.
- The Board will be expanded to 12 members with Sequeira joining the Talent Committee.
Organon (OGN), a leading global healthcare company specializing in women's health, today unveiled the appointment of Ramona A. Sequeira to its Board of Directors, effective from July 1, 2025. Sequeira, who currently serves as the President of the Global Portfolio Division at Takeda Pharmaceutical Company, will also join the Board's Talent Committee.
With this appointment, Organon's Board will expand to include 12 directors. Sequeira's extensive experience in the pharmaceutical sector spans over three decades, including two decades at Eli Lilly and a decade at Takeda. Her leadership at Takeda covers significant markets such as Europe, Canada, China, and emerging growth markets. She oversees the Vaccines Business Unit along with Global Medical and Commercial Strategy functions.
Sequeira's career highlights include her tenure as the first woman to chair the Pharmaceutical Research and Manufacturers of America's Board of Directors. She is currently on the board of Edwards Life Sciences, showcasing her vast experience and leadership in the industry. Organon is keen to leverage her commercial strategy expertise to pursue growth opportunities within its diverse portfolio.
"We are excited to strengthen our Board with the appointment of Ramona Sequeira," stated Carrie Cox, Chairman of Organon's Board of Directors. "Her deep experience in commercial strategy will be a valuable asset to Organon as we continue to seek growth opportunities for our expansive and diverse portfolio."
